Media coverage about Vericel (NASDAQ:VCEL) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Vericel earned a coverage optimism score of 0.24 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.5865539745687 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of VCEL stock traded down $0.25 during midday trading on Wednesday, hitting $11.10. The stock had a trading volume of 748,614 shares, compared to its average volume of 1,063,527. The stock has a market capitalization of $406.16, a PE ratio of -20.94 and a beta of 3.15. Vericel has a one year low of $2.35 and a one year high of $12.80. The company has a debt-to-equity ratio of 0.75, a quick ratio of 3.57 and a current ratio of 3.86.
Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Monday, March 5th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.13. The company had revenue of $23.35 million during the quarter. Vericel had a negative return on equity of 98.77% and a negative net margin of 27.04%. analysts predict that Vericel will post -0.24 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Vericel (NASDAQ:VCEL) Share Price” was first reported by BBNS and is the sole property of of BBNS. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://baseballnewssource.com/2018/03/21/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-vericel-vcel-stock-price/1923802.html.
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.